Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
Can a patient with a PMHx of pancreatic injury or disease (i.e. blunt trauma, recurrent pancreatitis) take a GLP-1 agonist safely in the setting of morbid obesity and type 2 diabetes?
Related Questions
Do you avoid empagliflozin in patients with history of amputation?
Are recurrent UTIs a contraindication to SGLT2i use?
When do you refer a patient with MODY3 to GI/Hepatology for monitoring/management of hepatic adenomas?
What is the recommended frequency and duration of exercise bouts in order to sustain the beneficial effects of exercise on insulin sensitivity?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
What is the therapeutic role and blood glucose lowering capability of Bromocriptine and Cholestyramine for the treatment of Type 2 diabetes?
Do you recommend the use of automated insulin delivery systems (such as Control IQ with Tandem insulin pumps) for managing gestational diabetes?
What is the typical timeline for remission of autoimmune hypoglycemia?
How do you adjust your management strategy to address the unique needs of anuric end-stage kidney disease patients when treating diabetic ketoacidosis?
